**6. Conclusion**

Antimicrobial resistant zoonotic bacteria pose a serious risk to human health. High rates of FQ resistance in both *Salmonella* and *Campylobacter* are of concern due to their wide use for the treatment of human infections. In some regions of the EU, the level of FQ resistance is so high that *Campylobacter* infections cannot be treated with FQ anymore. In addition, the emergence of multi-drug resistant *Salmonella* and *Campylobacter* further limits the therapy options and is possibly associated with adverse treatment effects. Greater efforts are needed to limit the wide spread of AMR in zoonotic bacteria—implementation of antimicrobial stewardship, especially in the developing countries, development of novel antimicrobials, improvement of practices in the food production chain, reduction of the amounts of antimicrobials sold for use in livestock, improvement of AMR surveillance programs, in terms of greater harmonisation, and application of rapid sequence-based methods in the routine surveillance of antimicrobial resistance.
